Who Paid My Doc
M23-362 Ph2 Epcoritamab RR DLBCL and FL Outpatient Study
ClinicalTrials.gov NCT05451810
Research payments
$20,071
Through program year 2024, $20,071 in research payments was reported against M23-362 Ph2 Epcoritamab RR DLBCL and FL Outpatient Study, across 71 payments, paid by AbbVie, Inc..
- Paid by
- AbbVie, Inc.
- ClinicalTrials.gov
- NCT05451810
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $20,071 | 71 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Richard Zuniga Babylon, NY Named on 4 payments
- Khoan Vu Dallas, TX Named on 2 payments
- Frederick Lansigan Lebanon, NH Named on 1 payment
- Kailash Mosalpuria Lincoln, NE Named on 1 payment
- Patricia Young Los Angeles, CA Named on 1 payment
- Paul Rubinstein Chicago, IL Named on 1 payment
- Ralph Boccia Bethesda, MD Named on 1 payment
- Chieh-Lin Fu Weston, FL Named on 1 payment
- Noridza Rivera Rodriguez San Juan, PR Named on 1 payment
- Alexander Philipovskiy Lake Mary, FL Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.